Fractionation of intravitreal syringes of aflibercept and ranibizumab, using an aseptic technique

Abstract

Introduction – Advances in ophthalmology and the discovery of antiangiogenic drugs administered by intravitreal injection have established a new way to treat retina diseases. The appearance of these drugs, in 2006, marked the approach and direction of age-related macular degeneration. The most commonly used anti-VEGF drugs for intravitreal injection are ranibizumab, bevacizumab, and aflibercept. These three drugs are commercially available in vials and do not need to be diluted or reconstituted. The solution only needs to be transferred aseptically into sterile syringes before administration. This method allows the entire content of a single-use vial can be divided into several syringes for storage and subsequent injection to different patients, enabling better management. Aim of the study – Describe a method used for fractionation of aflibercept and ranibizumab, using an aseptic technique. Methods – A narrative review of the literature was carried out. The method used was described according to the experience and procedures at the Professor Doutor Fernando Fonseca (HFF) Hospital pharmacy. Final considerations – In the context of the countless challenges facing healthcare institutions in Portugal and around the world, with a focus on their sustainability, the need to create strategies for managing medicines has become evident. For this reason, the fractionation of these drugs is dune, reducing costs and waste.